{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:43:11Z","timestamp":1792669391586,"version":"4.5.0"},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Metab"],"DOI":"10.1038\/s42255-026-01631-8","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:02:25Z","timestamp":1790154145000},"page":"2045-2047","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rare science, real impact: shaping the future of research on rare metabolic diseases"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4833-5195","authenticated-orcid":false,"given":"Anu","family":"Suomalainen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2705-7432","authenticated-orcid":false,"given":"Ralph J.","family":"DeBerardinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0582-540X","authenticated-orcid":false,"given":"Julien","family":"Baruteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4711-2248","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Puccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8490-7299","authenticated-orcid":false,"given":"Takanobu","family":"Otomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1723-6728","authenticated-orcid":false,"given":"Marni J.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"container-title":["Nature Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42255-026-01631-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-026-01631-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-026-01631-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:27:14Z","timestamp":1792668434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42255-026-01631-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":0,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["1631"],"URL":"https:\/\/doi.org\/10.1038\/s42255-026-01631-8","relation":{},"ISSN":["2522-5812"],"issn-type":[{"value":"2522-5812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"23 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.J.D. is an advisor for Vida Ventures, Faeth Therapeutics, Agios Pharmaceuticals, Alterris Oncology and Illumina; and is a founder and advisor at Atavistik Bioscience. J.B. has received research funding from Moderna, Insmed and the Citrin Foundation; and has received consultation fees from Satellite Bio, iECURE and Korro Bio. M.J.F. is engaged with companies involved in mitochondrial disease therapeutic preclinical and\/or clinical-stage development; is founder of Therapeutic Lighthouse Research Institute (TLRI, a 501c3 non-profit corporation) and M-Vortex; co-founder of Rarefy Therapeutics; an advisory board member with equity interest in RiboNova; a scientific advisory board member and paid consultant with Khondrion and Larimar Therapeutics; has been a paid consultant for Ajinomoto Cambrooke, Astellas (formerly Mitobridge), BPGbio (with equity interest), Casma Therapeutics, Cyclerion Therapeutics, Epirium Bio, Imel Therapeutics, Mayflower, Primera Therapeutics, Minovia Therapeutics, Mission Therapeutics, NeuroVive Pharmaceutical, Precision Biosciences, Reneo Therapeutics, Saol Therapeutics, Sironax, Stealth BioTherapeutics, Vincere Bio and Zogenix; and\/or as been a sponsored research collaborator for Aadi Biosciences, Adjuvia Therapeutics, Astellas, Cyclerion Therapeutics, Epirium Bio, Imel Therapeutics, Khondrion, Merck, Minovia Therapeutics, Mission Therapeutics, NeuroVive Pharmaceutical, Precision Biosciences, Pretzel Therapeutics, PTC Therapeutics, Raptor Pharmaceuticals, REATA, Reneo Therapeutics, RiboNova, Saol Therapeutics, Standigm, Stealth BioTherapeutics and Thiogenesis; and has received speaker fees from Chemistry Rx and royalty fees from Elsevier. None of these funders had any role in the conceptualization, design, data collection, analysis, decision to publish or preparation of the manuscript. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}